Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain
Johann S. de Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquı́n Mateo, Oliver Sartor, Kim N., Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Goessl, Joe Burgents
Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese, Omi Parikh, Simon J. Crabb, Angus Robinson, Duncan B. McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, George Seed, Cláudia Bertan, Penny Flohr, Berni Ebbs, ,
Discussion(0)
No comments yet. Be the first to comment.